Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks, am out, am just catching up. So readings numbers posted, we will be at the full 1.7 by end of Nov. Is that the consensus? (Someone else mentioned a balance for Dec)? If so really good news IMO, was very nervous about further delay.
Some great picks this month,1509 thanks as always.
Copl well spoken for so I’ll pass on that - I reckon we must have more than Art collectively.
If Arb can’t perform this month it never will and I’ll sell my LTH, so am going
Arb
Dev (market didn’t seem to like the RNS, but should rebound)
Eqt - news flow has started but am expecting more.
Pretty much there IMO, but with 2 caveats, obvious one about BTC holding firm plus also PW needs to RNS the expected new machines are being delivered and installed. PW low on trust at moment so if these are delayed again v bad for SP. He probably can’t RNS on this until Nov due to Nasdaq quiet period.
Problem is it’s only the Activ 2 news that can stop this drifting lower, yesterday that was enough to keep me in as I am still optimistic on it. But the Merck news will accelerate the sell off. Of course if Activ2 hits on Monday I will have made another mistake! But everything is very slow with Sng…
Hopefully you’re wrong given you bought back! It’s not that it has a lower efficacy just that, almost obviously, most non hospitalised people don’t need any drug, so you need much larger sample size, or just target those that do to get a statistical result. That was problem with their own home trial, not enough people. But for phase 2 progression, the way I understand it, as long as the signal that it works it there it should progress. But I’m not an expert, just waiting to see, but am hopeful.
Hi xviolet - why did you/do you think they might fail Activ? All the signs are they will progress, though lots of things to iron out like drug supply, funding etc. Though by no means a gimme. Anyway unless you sold very first thing SP probably back down to where you sold. I have a large position so am not adding. Just holding and see what happens with Activ.
I think there was also some bad blood with AZ from earlier interactions, and probably the U.K. govt were trying to force a link up with them with little economic value to SNG. The Oxford Astra alliance seem in control of all things COVID in the U.K. If you snub them you are in trouble. The whole COVID trials thing seems totally crooked to me, 15,000 people to trial aspirin, what a waste, SNG can’t even get 600 odd. Anyway that’s where we are and SNG now firmly pointed stateside, to me Activ 2 progression is a major thing because it will massively increase their reputation and profile in the US, so when they ask for the Sprinter EUA they are better known. Just my thoughts.
Hi Mumbo - I agree with everything you are saying, I’m just saying that for me it’s better to wait until after the activ news to consider selling rather than do so now, that’s why I’m holding. Of course if activ2 doesn’t progress that will be a big mistake. But market holding up well, so agreeing with me at the moment, but there is the analyst’s call at 1 that may change things again.
Hi Mumbo, yes the trial design was crazy, doing it across a silly number of countries, and basically they have shown themselves up as but small company that they are. But you can only look at where we are now when thinking about what to do with the holding, and activ2 p2 has completed with progression or non progression days or maybe a few weeks away. My view is progression very likely, then SP spikes. Non progression it falls. After that piece of news time to reassess again.
Clearly Sprinter delay not optimum, but at least we know where we are. Confirmation we r still in Activ 2 with p3 decision imminent - this is big plus as we must be likely to proceed. Positive tone about manufacturing and FDA approval path good as well. So overall mixed bag, but I held as if activ 2 p3 comes in next few days we are looking at big rise from here.